JSB Market reSearch: PharMaPoint: Ulcerative colitiS - GloBal DrUG ForecaSt anD Market analySiS to 2022 On 9th August 2014
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Overall, major barriers to the growth of the UC market include: Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
• Remicade and Humira losing patent protection in the mid-forecast • Austerity measures favoring generic prescribing • Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US • In 2012, GlobalData estimates that the global UC market reached $4.2 billion across the 10 healthcare markets covered in our forecast: the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India. By the end of the forecast period, in 2022, sales across these markets will grow steadily to reach $6.6 billion, representing a Compound Annual Growth Rate (CAGR) of 4.8% over the 10-year timeframe. Highlights Key Questions Answered • How will the UC market (sales and patient numbers) evolve over the 10-year forecast period from 2012 to 2022? • Which brands and specific drug classes did physicians select for their UC patients in 2012 and how do they foresee their prescribing behavior evolving over the next five years? • How will the launch of late-stage pipeline therapies such as Entyvio and Kappaproct shape the future treatment landscape? • What are the remaining unmet needs and opportunities for drug developers within the UC market? Key Findings • The UC market has predominantly been driven by two TNF blockers, namely J&Js Remicade and AbbVies Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takedas Entyvio imminently entering the market in 2014 and J&Js Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Simponi launching in 2014 as well, stealing market share from Humira and Remicade. • Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrions Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market. • During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizers Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis. Scope • Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. • Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022. • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics markets. • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs. • Analysis of the current and future market competition in the global UC therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
of its implications. Reasons to buy • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. • Develop business strategies by understanding the trends shaping and driving the global UC therapeutics markets. • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics markets in the future. • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. • Track drug sales in the global UC therapeutics markets from 2012-2022. • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Table of Contents: 1.1 List of Tables 1.2 List of Figures 2 Introduction 25 2.1 Catalyst 25 2.2 Related Reports 25 2.3 Upcoming Related Reports 25 3 Disease Overview 26 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
3.1 Etiology and Pathophysiology 26 3.1.1 Etiology 26 3.1.2 Pathophysiology 29 3.2 Symptoms 30 3.2.1 Quality of Life 31 4 Epidemiology 32 4.1 Disease Background 32 4.2 Risk Factors and Comorbidities 33 4.2.1 Being Caucasian and Jewish can increase the risk of UC by almost 37 times 34 4.2.2 A family history of UC in first-degree relatives can increase the risk of the disease by almost three-fold 34 4.2.3 Current smokers have a lower risk of developing UC than former smokers or never smokers 35 4.3 Global Trends 36 4.3.1 US 37 4.3.2 5EU 39 4.3.3 Japan 42 4.3.4 Canada 44 4.3.5 China 45 4.3.6 India 47 4.4 Forecast Methodology 48 4.4.1 Sources Used 50 4.4.2 Sources Not Used 56 4.4.3 Forecast Assumptions and Methods 57 4.5 Epidemiological Forecast of UC (2012-2022) 63 4.5.1 Incident Cases of UC 63 4.5.2 Age-Specific Incident Cases of UC 65 4.5.3 Sex-Specific Incident Cases of UC 66 4.5.4 Age-Standardized Incidence Rates 69 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
4.6 Epidemiological Forecast for UC Prevalent Cases (2012-2022) 70 4.6.1 Prevalent Cases of UC 70 4.6.2 Age-Specific Prevalent Cases of UC 72 4.6.3 Sex-Specific Prevalent Cases of UC 74 4.6.4 Age-Standardized Prevalence Rate of UC in All Markets 76 4.7 Discussion 77 4.7.1 Epidemiological Forecast Insight 77 4.7.2 Limitations of the Analysis 78 4.7.3 Strengths of the Analysis 79 5 Disease Management 80 5.1 Diagnosis and Treatment Overview 80 5.1.1 Diagnosis 80 5.1.2 Treatment Guidelines and Leading Prescribed Drugs 84 5.1.3 Clinical Practice 85 5.2 US 89 5.3 France 92 5.4 Germany 94 5.5 Italy 96 5.6 Spain 98 5.7 UK 100 5.8 Japan 102 5.9 Canada 104 5.10 China 106 5.11 India 108 6 Competitive Assessment 110 6.1 Overview 110 6.2 Strategic Competitor Assessment 111 6.3 Product Profiles - Major Brands 113 6.3.1 Remicade (infliximab) 113 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
6.3.2 Humira (adalimumab) 121 6.3.3 Simponi (golimumab) 127 6.3.4 Apriso (mesalamine) 131 6.3.5 Asacol HD (mesalamine) 137 6.3.6 Lialda (mesalamine) 142 6.3.7 Pentasa (mesalamine) 146 6.3.8 Colazal (balsazide disodium) 150 6.3.9 Giazo (balsalazide disodium) 154 6.3.10 sfRowasa (mesalamine) 158 6.3.11 Uceris (budesonide) 161 6.3.12 Other Drug Classes Used in the Treatment of UC 165 6.4 Biosimilars 166 6.4.1 Introduction 166 6.4.2 Hospiras Inflectra Versus J&Js Remicade in Key Autoimmune Diseases 167 6.4.3 Biosimilars in the Immunology Community 167 6.4.4 By the Numbers: Biosimilars in Development 168 6.4.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 170 6.4.6 Biosimilars Forecast 171 7 Opportunity and Unmet Need 173 7.1 Overview 173 7.2 Unmet Needs 174 7.2.1 Curative Therapy for Severe UC Patients 174 7.2.2 Diagnostic Markers for Disease Severity 174 7.2.3 Personalized Therapy 175 7.2.4 A Replacement for Steroids 175 7.2.5 Novel Oral Drug Formulations 176 7.2.6 Preventative Medicine for Lowering the Associated Colorectal Cancer Risk 177 7.2.7 Improved Management of Infectious Adverse Events 177 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
7.3 Unmet Needs Gap Analysis 178 7.4 Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools 179 7.5 Predictors of Medically-Refractory Disease 180 8 Pipeline Assessment 181 8.1 Overview 181 8.2 Clinical Trial Mapping 181 8.2.1 Clinical Trials by Country 181 8.3 Clinical Trials by Phase and Trial Status 182 8.4 Promising Drugs in Clinical Development 183 8.4.1 Entyvio (vedolizumab) 185 8.4.2 Xeljanz (tofacitinib) 195 8.4.3 Kappaproct (DIMS 0150) 202 9 Current and Future Players 208 9.1 Overview 208 9.2 Trends in Corporate Strategy 211 9.3 Company Profiles 212 9.3.1 Johnson & Johnson 212 9.3.2 AbbVie 214 9.3.3 Takeda Pharmaceuticals 216 9.3.4 Warner Chilcott 218 9.3.5 Salix Pharmaceuticals/Santarus 220 9.3.6 Shire Pharmaceuticals 222 9.3.7 Ferring Pharmaceuticals 224 9.3.8 Pfizer 225 9.3.9 InDeX Pharmaceuticals 227 10 Market Outlook 230 10.1 Global Markets 230 10.1.1 Forecast 230 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
10.1.2 Drivers and Barriers - Global Issues 235 10.2 United States 239 10.2.1 Forecast 239 10.2.2 Key Events 243 10.2.3 Drivers and Barriers 243 10.3 France 246 10.3.1 Forecast 246 10.3.2 Key Events 250 10.3.3 Drivers and Barriers 250 10.4 Germany 253 10.4.1 Forecast 253 10.4.2 Key Events 257 10.4.3 Drivers and Barriers 257 10.5 Italy 259 10.5.1 Forecast 259 10.5.2 Key Events 263 10.5.3 Drivers and Barriers 263 10.6 Spain 265 10.6.1 Forecast 265 10.6.2 Key Events 269 10.6.3 Drivers and Barriers 269 10.7 United Kingdom 271 10.7.1 Forecast 271 10.7.2 Key Events 275 10.7.3 Drivers and Barriers 275 10.8 Japan 277 10.8.1 Forecast 277 10.8.2 Key Events 281 10.8.3 Drivers and Barriers 281 10.9 Canada 284 10.9.1 Forecast 284 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
10.9.2 Key Events 287 10.9.3 Drivers and Barriers 287 10.10 China 289 10.10.1 Forecast 289 10.10.2 Key Events 291 10.10.3 Drivers and Barriers 292 10.11 India 294 10.11.1 Forecast 294 10.11.2 Key Events 296 10.11.3 Drivers and Barriers 297 11 Appendix 300 11.1 Bibliography 300 11.2 Abbreviations 311 11.3 Methodology 316 11.4 Forecasting Methodology 316 11.4.1 Diagnosed UC Patients 316 11.4.2 Percent Drug-Treated Patients 317 11.4.3 Drugs Included in Each Therapeutic Class 317 11.4.4 Launch and Patent Expiry Dates 317 11.4.5 General Pricing Assumptions 318 11.4.6 Individual Drug Assumptions 319 11.4.7 Generic Erosion 321 11.4.8 Pricing of Pipeline Agents 321 11.5 Physicians and Specialists Included in This Study 322 11.6 Primary Research - Prescriber Survey 324 11.7 About the Authors 325 11.7.1 Author 325 11.7.2 Epidemiologist 326 11.7.3 Global Head of Healthcare 326 11.8 About GlobalData 327 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
11.9 Disclaimer 327 List of Tables Table 1: Genetic Factors That Confer a Predisposition to UC 28 Table 2: Typical Symptoms of UC 30 Table 3: Strongest Putative Risk Factors for UC 34 Table 4: Prevalence of UC in the US 39 Table 5: Incidence of UC in the 5EU 40 Table 6: Prevalence of UC in the 5EU 41 Table 7: 10MM, Sources of UC Incidence Data Used in the Epidemiological Forecast 48 Table 8: 10MM, Sources of UC Prevalence Data Used in the Epidemiological Forecast 49 Table 9: 10MM, Incident Cases of UC, Ages ?10 Years, Both Sexes, N, Select Years, 2012-2022 64 Table 10: 10MM, Incident Cases of UC, By Age, Both Sexes, N (Row %), 2012 65 Table 11: 10MM, Incident Cases of UC, By Sex, Ages ?10 Years, N (Row %), 2012 67 Table 12: 10MM, Prevalent Cases of UC, Ages ?10 Years, Both Sexes, N, Select Years, 2012-2022 71 Table 13: 10MM, Prevalent Cases of UC, By Age, Both Sexes, N (Row %), 2012 73 Table 14: 10MM, Prevalent Cases of UC, By Sex, Ages ?10 Years, N (Row %), 2012 75 Table 15: Truelove and Witts UC Severity Index 82 Table 16: UCDAI 83 Table 17: Treatment Guidelines for UC Used in the 10MM 84 Table 18: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013 85 Table 19: UC Management Country Profile - US 91 Table 20: UC Management Country Profile - France 93 Table 21: UC Management Country Profile - Germany 95 Table 22: UC Management Country Profile - Italy 97 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 23: UC Management Country Profile - Spain 98 Table 24: UC Management Country Profile - UK 101 Table 25: UC Management Country Profile - Japan 103 Table 26: Country Profile - Canada 105 Table 27: UC Management Country Profile - China 107 Table 28: UC Management Country Profile - India 109 Table 29: Leading Treatments for UC, 2014 112 Table 30: Product Profile - Remicade 115 Table 31: Remicade SWOT Analysis, 2014 119 Table 32: Global Sales Forecasts ($m) for Remicade, 2012-2022 120 Table 33: Product Profile - Humira 122 Table 34: Humira Efficacy in the ULTRA 2 Trial 123 Table 35: Product Efficacy Comparison - Humira vs. Remicade 123 Table 36: Humira SWOT Analysis, 2014 125 Table 37: Global Sales Forecasts ($m) for Humira, 2012-2022 126 Table 38: Product Profile - Simponi 128 Table 39: Simponi SWOT Analysis, 2014 130 Table 40: Global Sales Forecasts ($m) for Simponi, 2012-2022 131 Table 41: Product Profile - Apriso 133 Table 42: Apriso SWOT Analysis, 2014 135 Table 43: Global Sales Forecasts ($m) for Apriso, 2012-2022 136 Table 44: Product Profile - Asacol HD 138 Table 45: Asacol HD SWOT Analysis, 2014 141 Table 46: Global Sales Forecasts ($m) for Asacol HD, 2012-2022 142 Table 47: Product Profile - Lialda 143 Table 48: Lialda SWOT Analysis, 2014 145 Table 49: Global Sales Forecasts ($m) for Lialda, 2012-2022 146 Table 50: Product Profile - Pentasa 147 Table 51: Pentasa SWOT Analysis, 2014 149 Table 52: Global Sales Forecasts ($m) for Pentasa, 2012-2022 150 Table 53: Product Profile - Colazal 151 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 54: Colazal SWOT Analysis, 2014 153 Table 55: Global Sales Forecasts ($m) for Colazal, 2012-2022 154 Table 56: Product Profile - Giazo 155 Table 57: Giazo SWOT Analysis, 2014 157 Table 58: Global Sales Forecasts ($m) for Giazo, 2012-2022 158 Table 59: Product Profile - sfRowasa 159 Table 60: sfRowasa SWOT Analysis, 2014 160 Table 61: Global Sales Forecasts ($m) for sfRowasa, 2012-2022 161 Table 62: Product Profile - Uceris 162 Table 63: Uceris SWOT Analysis, 2014 164 Table 64: Global Sales Forecasts ($m) for Uceris, 2012-2022 165 Table 65: Summary of Other Immunomodulators for UC, 2013 166 Table 66: Biosimilars Pipeline, 2013 168 Table 67: Global Sales Forecasts ($m) for Infliximab Biosimilars, 2012-2022 171 Table 68: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 2012-2022 171 Table 69: Global Sales Forecasts ($m) for Golimumab Biosimilars, 2012-2022 172 Table 70: Overall Unmet Needs - Current Level of Attainment 173 Table 71: Corticosteroid Long-Term Side Effects 176 Table 72: Clinical Unmet Needs in UC - Gap Analysis, 2013 179 Table 73: Prognostic Markers in UC 180 Table 74: UC - Clinical Trials by Phase and Status, 2014 183 Table 75: UC - Pre-Registration and Phase III Pipeline, 2014 183 Table 76: Comparison of Therapeutic Classes in Development for UC, 2014 184 Table 77: Product Profile - Entyvio 187 Table 78: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Induction of Remission in UC 188 Table 79: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Maintenance of Remission in UC 189 Table 80: Most Common Adverse Events with Vedolizumab in the GEMINI I Study 190 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 81: Entyvio SWOT Analysis, 2014 193 Table 82: Global Sales Forecasts ($m) for Entyvio, 2012-2022 195 Table 83: Product Profile - Xeljanz 196 Table 84: Results of Phase IIa Trial of Xeljanz in the Induction of Remission in UC 197 Table 85: Most Common Adverse Events in the Phase IIa Trial of Xeljanz 199 Table 86: Xeljanz SWOT Analysis, 2014 201 Table 87: Global Sales Forecasts ($m) for Xeljanz, 2012-2022 202 Table 88: Product Profile - Kappaproct 203 Table 89: Results of Phase IIb Trial of Kappaproct in the Induction of Remission in UC 204 Table 90: Kappaproct SWOT Analysis, 2014 206 Table 91: Global Sales Forecasts ($m) for Kappaproct, 2012-2022 207 Table 92: Key Companies in the UC Market, 2012-2022 209 Table 93: J&Js UC Portfolio Assessment, 2014 213 Table 94: J&Js SWOT Analysis in UC, 2014 214 Table 95: AbbVies UC Portfolio Assessment, 2014 215 Table 96: AbbVies UC SWOT Analysis, 2014 216 Table 97: Takeda Pharmaceuticals UC Portfolio Assessment, 2014 217 Table 98: Takedas UC SWOT Analysis, 2014 218 Table 99: Warner Chilcotts UC Portfolio Assessment, 2014 219 Table 100: Warner Chilcotts UC SWOT Analysis, 2014 220 Table 101: Salix Pharmaceuticals/Santarus UC Portfolio Assessment, 2013 221 Table 102: Salix Pharmaceuticals/Santarus UC SWOT Analysis, 2014 222 Table 103: Shire Pharmaceuticals UC Portfolio Assessment, 2014 223 Table 104: Shire Pharmaceuticals UC SWOT Analysis, 2014 223 Table 105: Ferring Pharmaceuticals UC Portfolio Assessment, 2013 224 Table 106: Ferring Pharmaceuticals UC SWOT Analysis, 2014 225 Table 107: Pfizers UC Portfolio Assessment, 2014 226 Table 108: Pfizers UC SWOT Analysis, 2014 227 Table 109: InDeX Pharmaceuticals UC Portfolio Assessment, 2013 228 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 110: InDeX Pharmaceuticals UC SWOT Analysis, 2014 229 Table 111: Global Sales Forecasts ($m) for UC, 2012-2022 232 Table 112: Global UC Market - Drivers and Barriers, 2012-2022 235 Table 113: Sales Forecasts ($m) for UC in the US, 2012-2022 241 Table 114: Key Events Impacting Sales for UC in the US, 2012-2022 243 Table 115: UC Market in the US - Drivers and Barriers, 2012-2022 243 Table 116: Sales Forecasts ($m) for UC in France, 2012-2022 247 Table 117: Key Events Impacting Sales for UC in France, 2012-2022 250 Table 118: UC Market in France - Drivers and Barriers, 2012-2022 250 Table 119: Sales Forecasts ($m) for UC in Germany, 2012-2022 255 Table 120: Key Events Impacting Sales for UC in Germany, 2012-2022 257 Table 121: UC Market in Germany - Drivers and Barriers, 2012-2022 257 Table 122: Sales Forecasts ($) for UC in Italy, 2012-2022 261 Table 123: Key Events Impacting Sales for UC in Italy, 2012-2022 263 Table 124: UC Market in Italy - Drivers and Barriers, 2012-2022 263 Table 125: Sales Forecast List of Figures Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC 30 Figure 2: Olmsted Country, Minnesota, US, Age- and Sex-Adjusted Incidence of UC, Cases per 100,000 Population, 1940-2000 38 Figure 3: Canada, Incidence and Prevalence of UC, Cases per 100,000 Population, 1990-2001 44 Figure 4: Hong Kong, China, Crude Incidence and Prevalence of UC, Cases per 100,000 Population, 1997-2006 46 Figure 5: 10MM, Incident Cases of UC, Ages ? 10 Years, Both Sexes, N, 2012-2022 64 Figure 6: 10MM, Incident Cases of UC, By Age, Both Sexes, N, 2012 66 Figure 7: 10MM, Incident Cases of UC, By Sex, Ages ?10 Years, N, 2012 68 Figure 8: 10MM, Age-Standardized Incidence of UC, Ages ?10 Years, Both Sexes, Cases per 100,000 Population, 2012 69 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 9: 10MM, Prevalent Cases of UC, Ages ?10 Years, Both Sexes, N, 2012-2022 72 Figure 10: 10MM, Prevalent Cases of UC, By Sex, Ages ? 10 Years, N, 2012 74 Figure 11: 10MM, Prevalent Cases of UC, By Sex, Ages ?10 Years, N, 2012 76 Figure 12: 10MM, Age-Standardized Prevalence of UC, Ages ?10 Years, Both Sexes, %, 2012 77 Figure 13: UC Disease Management Flowchart 88 Figure 14: UC Therapeutics - Clinical Trials by Country, 2014 182 Figure 15: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012-2022 184 Figure 16: Company Portfolio Gap Analysis in UC, 2012-2022 210 Figure 17: Global Sales for UC by Region, 2012 (Total: $m)-2022 (Total: $m) 234 Figure 18: Sales for UC in the US by Drug Class, 2012-2022 242 Figure 19: Sales for UC in France by Drug Class, 2012-2022 249 Figure 20: Sales for UC in Germany by Drug Class, 2012-2022 256 Figure 21: Sales for UC in Italy by Drug Class, 2012-2022 262 Figure 22: Sales for UC in Spain by Drug Class, 2012-2022 268 Figure 23: Sales for UC in the UK by Drug Class, 2012-2022 274 Figure 24: Sales for UC in Japan by Drug Class, 2012-2022 280 Figure 25: Sales for UC in Canada by Drug Class, 2012-2022 286 Figure 26: Sales for UC in China by Drug Class, 2012-2022 291 Figure 27: Sales for UC in India by Drug Class, 2012-2022 296
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Related reports: Molecular Diagnostics Market by Application (Infectious Disease, Oncology, Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), Product (Instruments, Reagent, Service, Software) - Global Forecasts to 2018 Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging, Whole Breast Ultrasound, Breast Thermography) - Global Forecasts to 2019 Healthcare and Medical Market Research
About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is one-stop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience. To know more on PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
http://www.jsbmarketresearch.com/healthcaremedical/r-PharmaPoint-Ulcerative-Colitis-Global-DrugForecast-and-Market-Analysis-114234 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/